Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive to share details about the company that is personalizing cancer treatment using CAR-T cell therapy.
Yatomi -Clarke telling Proactive about their work and also some recent big news for the company including being issued two U.S. patents.